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Abstract
Background: Removal of phosphate by peritoneal dialysis is insufficient to maintain normal serum phosphate
levels such that most patients must take phosphate binders with their meals. However, phosphate ‘counting’ is
complicated and many patients are simply prescribed a specific dose of phosphate binders with each meal.
Therefore, our primary objective was to assess the variability in meal phosphate content to determine the
appropriateness of this approach.
Methods: In this prospective cohort study, adult patients with ESRD treated with peritoneal dialysis and prescribed
phosphate binder therapy were eligible to participate. Participants were excluded from the study if they were unable
to give consent, had hypercalcemia, were visually or hearing impaired or were expected to receive a renal transplant
during the time of the study. After providing informed consent, patients kept a 3-day diet diary that included all
foods and beverages consumed in addition to portion sizes. At the same time, patients documented the amount of
phosphate binders taken with each meal. The phosphate content of the each meal was estimated using ESHA Food
Processor SQL Software by a registered dietitian. Meal phosphate and binder variability were estimated by the Intra
Class Correlation Coefficient (ICC) where 0 indicates maximal variability and 1 indicates no variability.
Results: Seventy-eight patients consented to participate in the study; 18 did not complete the study protocol.
The patients were 60 (±17) years, predominately male (38/60) and Caucasian (51/60). Diabetic nephropathy was
the most common cause of end stage kidney disease. The daily phosphate intake including snacks ranged from
959 ± 249 to 1144 ± 362 mg. The phosphate ICC by meal: breakfast 0.63, lunch 0.16; supper 0.27. The phosphate
binder ICC by meal: breakfast 0.68, lunch 0.73, supper 0.67.
Conclusion: The standard prescription of a set number of phosphate binders with each meal is not supported
by the data; patients do not appear to be adjusting their binders to match the meal phosphate content. An easy
to use phosphate counting program that assists the patient in determining the appropriate amount of phosphate
binder to take may enhance phosphate control.
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Background
Helping patients with end stage renal disease (ESRD)
maintain a normal serum phosphate level remains a
challenge for many healthcare practitioners. Hyperpho-
sphatemia, a condition in which the renal filtration and
excretion of phosphate decreases as chronic kidney disease
(CKD) advances, has been independently associated with
adverse outcomes including abnormal bone and mineral
metabolism [1], vascular and soft tissue calcification [2, 3],
and cardiovascular morbidity and mortality in patients
treated with hemodialysis and peritoneal dialysis [4–6]. In
an attempt to mitigate this risk, the 2009 Kidney Disease
Improving Global Outcomes (KDIGO) guidelines included
targets for serum phosphate [7], but several studies
have shown that achieving serum phosphate of 3.5 and
5.5 mg/dL (1.1–1.8 mmol/L) is difficult for a large portion
of patients treated with dialysis [5, 8–10].
The treatment of hyperphosphatemia in dialysis patients
includes many factors: adequate dialysis, dietary phosphate
restriction, and phosphate-binding agents. Conventional
hemodialysis and peritoneal dialysis provide inadequate
phosphate removal alone such that almost all patients will
be in a positive phosphate balance [11]. Nutritional inter-
ventions to control phosphate intake attempt to limit the
amount of daily phosphate from foods to 800 to 1100 mg
of phosphate per day [7]. In addition to dietary prescrip-
tions, intense educational strategies to increase patient
knowledge about dietary phosphate have been shown to
be effective in lowering serum phosphate, but long inter-
ventions (≥4 months) may be needed for sustained benefit
[12, 13]. Dietician efforts are hampered by poor compli-
ance to diet which is a prevalent theme among patients
treated with dialysis [14–17]. Also, overly restrictive diets
may be complicated to follow and may negatively impact a
patient’s nutritional status, resulting in protein calorie
malnutrition and a greater risk of death [18]. Lastly phos-
phate binders can be taken with meals to limit intestinal
absorption of phosphate; none are without their limita-
tions. Since its introduction, calcium carbonate remains in
wide use today primarily because of its low cost compared
to other phosphate binders. Calcium carbonate, however,
may predispose some dialysis patients to hypercalcemia,
especially if the dosing is mistimed with meals [11].
Despite the presumed variability in daily meal phosphate
consumption, it is common to prescribe a fixed dose of
phosphate binders that does not necessarily mirror the
day-to-day and meal-to-meal changes in phosphate intake.
This variation in phosphate intake could lead to a mis-
match between phosphate intake and phosphate binder
dose resulting in an increase in phosphate or calcium ab-
sorption [19]. Unnecessarily increasing phosphate binder
fixed dosing in an attempt to reduce serum phosphate can
increase pill burden and contribute to reduced medication
adherence [20].
Based on the premise that self-adjustment of phosphate
binders by dialysis patients using a mobile application may
improve phosphate control, the aim of this 3-phase study
is to develop a novel phosphate counting program for the
Apple iPod touch device. Phase 1 of the study was to
determine the daily meal phosphate variability to ensure
that development of such an application is warranted.
Methods
The study was approved by the Ottawa Health Science
Research Ethics Network (ID 20120105-01H). Patients
were recruited from The Ottawa Hospital Home Dialysis
Unit in Ottawa, Canada from July 2012 through October
2014. English or French speaking/writing adult patients
who had ESRD treated with peritoneal dialysis and phos-
phate binder therapy were eligible for participation.
Participants were excluded from the study if they (i)
were unable or unwilling to give informed consent, (ii) had
hypercalcemia, (iii) were visually or hearing impaired or (iv)
were expected to receive a renal transplant during the time
of the study. After obtaining informed consent, patients
were taught to use a registered dietitian (RD) developed
food journal. One week prior to their next routine clinic
visit, participants were asked to document their food and
beverage intake, and the number of phosphate binders
taken at meals for 3 days using the food journals. Pre-clinic
biochemistry tests including serum calcium, phosphate, and
parathyroid hormone, and a standard adequacy assessment
using the Baxter Adequest program (Baxter Healthcare,
Deerfield, Il) were performed. The completed food journals
were reviewed by the RD to ensure accuracy; patients were
contacted as necessary to confirm serving sizes, brand
names, and food type. To calculate the phosphate content
of the foods and beverages, the ESHA Food Processor SQL
Software was used; although infrequent, other sources of
data were used for foods not found in the software (e.g. cer-
tain cheeses, cereals, and snacks) including published man-
uscripts (USDA National Nutrient Database for Standard
Reference, Release 25), government nutrient databases
(Food Standards Australia New Zealand’s NUTTAB 2010
Online Searchable Database), and the food manufacturer.
Data including basic patient characteristics was en-
tered into an Excel spreadsheet. Summary descriptive
statistics to describe the population, mean and standard
deviation for phosphate intake and phosphate binder
dose taken were calculated. Box and whisker plots for
the 3-day phosphate intake by meal were created. Intra-
class correlation coefficients (ICC) for meal phosphate
content and phosphate binders taken with the meals
were calculated using SAS 9.3 SAS Institute Inc., Cary,
NC, USA. The ICC is a descriptive statistic that allows
an assessment of how strongly units (e.g. phosphate) in
the same group (e.g. breakfast) are similar to each other.
The ICC value ranges from 0 to 1; as the ICC increases
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the more the units in the group resemble each other. An
ICC of > 0.75 suggests that the units in the group are
very similar to each other.
Results
Participants and recruitment
A total of 150 patients were screened for the study.
Twenty-two patients were not eligible (prior to consent
3 patients died, 9 patients received renal transplants, 6
patients switched to hemodialysis, 2 patients recovered
renal function, and 2 patients were not taking a phos-
phate binder). Fifty patients declined to participate.
Seventy-eight peritoneal dialysis patients consented to
the study, 60 (38 men and 22 women) completed the
study protocol (Table 1). Reasons for participant with-
drawal from the study included: 3 received a kidney
transplant, 1 died, 5 withdrew consent, 7 were unable or
unwilling to follow the protocol, and 2 were found to be
ineligible.
On average patients were 60 ± 17 years old, predomin-
ately Caucasian and 50 % had a history of diabetes mellitus
(Table 1). The majority of patients were taking calcium
carbonate as their phosphate binder with an average pre-
scribed elemental calcium dose per day of 800 ± 440 mg
per day. Only 6 of the patients were using sevelamer
hydrochloride as a phosphate binder. Total daily phos-
phate intake including snacks over the 3 days ranged from
959 ± 249 mg to 1144 ± 362 mg per day with the majority
of phosphate being consumed with supper (Table 2).
Meal phosphate intake ranged from a minimum to a
maximum of 0 to 798 mg for breakfast, 0 to 1853 mg for
lunch and 0 to 1523 mg for supper (Fig. 1). There was also
tremendous variability in the amount of phosphate
consumed with snacks ranging from 0 to 463 mg per
snack with some patients consuming 3 snacks in 1 day.
The ICCs meal phosphate content was: Breakfast = 0.63;
Lunch = 0.16; Supper = 0.27. The ICCs for phosphate
binders taken with the meals were: Breakfast = 0.68;
Lunch = 0.73; Supper = 0.67.
Discussion
In our prospective cohort of patients with ESRD treated
with peritoneal dialysis, we have shown that the ICCs as-
sociated with meal phosphate content, with the excep-
tion of breakfast, are highly variable and do not support
a standard number of phosphate binders to be order for
each meal. Despite dietician review at each clinic visit,
the ICCs for meal binder use suggest that patients follow
fixed binder dosing as prescribed and are not varying their
phosphate binders to the extent that meal phosphate con-
tent changes. This variability in meal phosphate intake with
relatively fixed phosphate binder dosing may contribute to
the poor phosphate control experienced by patients on dia-
lysis. Our results are in agreement with one previous study
of 16 pediatric patients with chronic kidney disease [21].
In spite of these issues, normalizing serum phosphate
levels with phosphate binders is possible. During the
first 12 weeks in the Treat-to-Goal study involving 200
hemodialysis patients, the phosphate binder dose was
titrated every 3 weeks until the patient’s serum phosphate
concentration fell between 3.0 to 5.0 mg/dL (1–1.6 mmol/
L) [22]. However, it is possible that mismatched timing of
meal phosphate intake and binder dose may lead to an in-
creased number of phosphate binders being taken than are
required. Better knowledge of phosphate dietary restrictions
may improve serum phosphate [23]; Karavetian et al. found
in a recent meta-analysis that all but one of the 18 studies
that met their inclusion criteria reported either a significant
(14 of the 18 studies) or a non-significant reduction in
serum phosphate levels, which ranged from 0.3 to
1.6 mg/dL (average: 1 mg/dL; 0.01–0.5 mmol/L), when
hemodialysis patients received nutrition counseling.
The interventions were highly variable and lasted 20–
40 minutes in just one session to as many as eight ses-
sions per month for 1 to 6 months [13]. The authors
identified the effective strategies that contributed to
dietary behavior change included high-intensity educa-
tion, long duration of intervention, and individualized
counseling by a renal dietitian. For example in a study
by Yokum et al., serum phosphate levels were signifi-
cantly reduced in the intervention group compared to
standard of care group over a 4 month period but both
a dietitian and pharmacist were part of the phosphate
lowering intervention strategy [24]. Although this in-
tensive and time consuming education appears to be
effective in reducing serum phosphate, time may be a
limited commodity for dietitians in most dialysis centers
such that achieving phosphate control may be very diffi-
cult in a routine clinical care setting [25].
To further complicate the issue, more education time
does not necessarily equate to improvements in serum
phosphate concentration over time. Ashurst et al. provided
participants in their intervention group with a onetime 40-
min dietetic education session just prior to hemodialysis,
Table 1 Baseline patient demographics
Patient Characteristics
Age – Years (SD) 60 (17)
Sex (M:F) 38:22
Race N (%) Caucasian 51 (85) Aboriginal 1 (2)
African American 3 (5) Asian 5 (8)
DM N (%) 30 (50)
Etiology of ESRD N (%) DM 18 (30) PKD 8 (13) GN 6 (10)
Other 28 (47)
Calcium Based Binders N (%) 57 (95)
Sevelemer N (%) 6 (10)
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and this intervention was shown to significantly reduce and
maintain the serum phosphate levels over a 3 month period
[26]. However in a study by Morey et al. study, monthly
dietetic consultation resulted in significantly decreased
serum phosphate levels by the third month, but by the six
month these levels were neither sustained nor significantly
different from baseline [27]. Importantly, although the
study protocol and the length of the intervention periods
of Yokum et al., Morey et al., and Ashurst et al. differed,
all three studies also included education regarding the
proper use of phosphate binders. None of the authors dis-
tinguished how much of the improvements in serum
phosphate levels was a result of dietary restriction versus
phosphate binder adherence. Thus, a simpler approach
that combines both dietary and phosphate binder educa-
tional elements into one novel tool to help dialysis patients
manage serum phosphate levels may be useful.
An innovative concept was developed to account for
the discrepancy between the phosphate binder dose and
the differences in phosphate quantities at meals. Patients
who were instructed in the ‘Phosphate Education Program’
(PEP) would self-adjust his or her phosphate binder
dose to the amount of phosphate at each meal by first
eye-estimating the amount of phosphate using ‘Phosphate
Units’ (PU). PU was a predefined amount of phosphate in a
food based on the major food group it belongs to, and then
the patient would apply a phosphate binder/PU ratio pre-
scribed by the physician titrated to the patient’s predialysis
Table 2 Meal phosphate content and phosphate binder dose by meal
aDaily mean phosphate intake in mg (SD) Phosphate binder intake (mg) Meal Mean meal phosphate intake in mg (SD)
1144 (362) 627 (542) Breakfast (Day 1) 215 (162)
848 (727) Lunch 302 (247)
978 (684) Supper 566 (186)
973 (283) 581 (589) Breakfast (Day 2) 183 (83)
678 (726) Lunch 256 (156)
959 (732) Supper 462 (218)
959 (249) 545 (558) Breakfast (Day 3) 239 (119)
686 (713) Lunch 233 (148)
1000 (726) Supper 437 (158)
atotal includes snacks
mg milligrams, SD standard deviation
Fig. 1 Meal Phosphate Variability
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serum phosphate concentration [19, 21]. This concept was
trialed with pediatric CKD patients in a non-randomized
prospective study (n = 16), which found that self-
adjustment of phosphate binder dose in relation to
meal phosphate content improved the management of
hyperphosphatemia within 6 weeks after PEP training
but the statistically significant effect was not sustained.
PEP training included a workshop, an individualized con-
sult with the dietitian, and a separate meeting with the
pediatric nephrologist [21]. The PEP improves upon the
current practice of fixed phosphate binder doses, but this
approach may be too difficult for many patients.
Mobile applications can be practical tools in the self-
management of diabetes and are preferred for their ease
of use over web- or computer-based programs [28].
Importantly, mobile applications have been shown to
improve glycemic control in people living with type-1
diabetes [29, 30]. Although several technology-based
tools for the management of CKD are available, a novel
‘phosphate counting’ program for the Apple iPod touch
device to teach patients how to ‘match’ phosphate binders
to the amount of phosphate in food does not exist. Devel-
opment of such an APP may increase phosphate binder
adherence, better match phosphate binder dose to phos-
phate intake, and improve serum phosphate levels.
Conclusion
The standard practice of prescribing fixed doses of phos-
phate binders at meals is an inappropriate management
strategy for the control of serum phosphate concentra-
tion as meal phosphate intake is highly variable as was
demonstrated in this study. Intensive dietary education
remains a cornerstone of phosphate management, but
such interventions are time consuming and dialysis facilities
may not have sufficient resources to meet the educational
needs of their patients. Although an innovative approach to
empower patients to self-adjust their phosphate binder dose
based on phosphate intake has been developed and tested,
a simpler method that takes advantage of mobile applica-
tion technology may improve phosphate binder compliance
and management of hyperphosphatemia.
Competing interests
BM has the following disclosures that are unrelated to this submission:
Baxter-consulting, speaker board; Concert Pharmaceuticals- consulting;
Sanofi- Advisory board. BM and DZ have the following disclosure related to
this submission: Baxter- research grant. The other authors have no competing
interests to declare.
Authors’ contributions
BM and DZ conceived of the study, and participated in its design and
coordination and helped to draft the manuscript. SL, JW, MB and SL
participated in the conduct of the study. All authors read and approved
the final manuscript.
Acknowledgements
Statistical support provided by the Ottawa Hospital Methods Centre. Drs
McCormick and Zimmerman receive salary support from the Department of
Medicine at the Ottawa Hospital and Clinical Trials support from the Kidney
Research Centre. This study was funded by a Baxter Renal Discoveries
Extramural Grant. The study would not have been possible without the
support of the staff and patients of the Ottawa Hospital Home Dialysis Unit.
Author details
1Division of Endocrinology, Department of Medicine, Ottawa Hospital,
Ottawa, ON, Canada. 2Division of Nephrology, Department of Medicine,
Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada. 3Kidney Research
Centre, Ottawa Hospital Research Institute, Ottawa, ON, Canada. 4Department
of Medicine, University of Ottawa, Ottawa, ON, Canada. 5Riverside Campus of
the Ottawa Hospital, 1967 Riverside Dr, Ottawa, ON K0A 2Z0, Canada.
Received: 28 July 2015 Accepted: 3 December 2015
References
1. Martin KJ, Gonzalez EA. Prevention and control of phosphate retention/
hyperphosphatemia in CKD-MBD: what is normal, when to start, and how
to treat? Clin J Am Soc Nephrol. 2011;6:440–6.
2. Delmez J, Slatopolsky E. Hyperphosphatemia, its consequence and treatment
in patients with chronic renal failure. Am J Kidney Dis. 1992;4:313–7.
3. Lowrie EG, Lew NL. Death risk in haemodialysis patients: the predictive
value of commonly measured variables and an evaluation of death rate
differences between facilities. Am J Kidney Dis. 1990;15:458–82.
4. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM.
Mineral metabolism, mortality, and morbidity in maintenance hemodialysis.
J Am Soc Nephrol. 2004;15(8):2208–18.
5. Noordzij M, Korevaar JC, Boeschoten EW, Dekker FW, Bos WJ, Krediet RT.
The Kidney Disease Outcomes Quality Initiative (K/DOQI) guideline for bone
metabolism and disease in CKD: Association with mortality in dialysis
patients. Am J Kidney Dis. 2005;46:925–32.
6. Ansell D. Serum phosphate and outcomes in PD patients. Nephrol Dial
Transplant. 2007;22:667–8.
7. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work
Group. KDIGO clinical practice guideline for the diagnosis, evaluation,
prevention, and treatment of Chronic Kidney Disease-Mineral and Bone
Disorder (CKD-MBD). Kidney Int Suppl. 2009;113:S1–130.
8. Blayney MJ, Tentori F. Trends and consequences of mineral bone disorder
in haemodialysis patients: lessons from the Dialysis Outcomes and Practice
Patterns Study (DOPPS). J Ren Care. 2009;35:7–13.
9. Young EW, Akiba T, Albert JM, McCarthy JT, Kerr PG, Mendelssohn DC. et al.
Magnitude and impact of abnormal mineral metabolism in hemodialysis
patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am
J Kidney Dis. 2004;44(5 Suppl 2):34–8.
10. Al Aly Z, González EA, Martin KJ, Gellens ME. Achieving K/DOQI laboratory
target values for bone and mineral metabolism: an uphill battle. Am J
Nephrol. 2004;24(4):422–6.
11. Coladonato JA. Control of Hyperphosphatemia among Patients with ESRD.
J Am Soc Nephrol. 2005;16:S107–14.
12. Caldeira D, Amaral T, David C, Sampaio C. Educational strategies to reduce
serum phosphorus in hyperphosphatemic patients with chronic kidney
disease: Systematic review with meta-analysis. J Ren Nutr. 2011;21:285–94.
13. Karavetian M, de Vries N, Rizk R, Elzein H. Dietary educational interventions
for management of hyperphosphatemia in hemodialysis patients: a
systematic review and meta-analysis. Nutr Rev. 2014;72(7):471–82.
14. Denhaerynck K, Manhaeve D, Dobbels F. Prevalence and consequences of
nonadherence to hemodialysis regimens. Am J Crit Care. 2007;16:222–35.
15. Kugler C, Maeding I, Russell CL. Non-adherence in patients on chronic
hemodialysis: an international comparison study. J Nephrol.
2011;24:366–75.
16. Nerbass FB, Morais JG, dos Santos RG, Krüger TS, Koene TT, da Luz Filho HA.
Adherence and knowledge about hyperphosphatemia treatment in
hemodialysis patients with hyperphosphatemia. J Bras Nefrol. 2010;32(2):149–55.
17. Griva K, Lai AY, Lim HA, Yu Z, Foo MWY, Newman SP. Non-Adherence in
Patients on Peritoneal Dialysis: A Systematic Review. PLoS ONE. 2014;9(2):e89001.
18. Rufino M, de Bonis E, Martin M, Rebollo S, Martin B, Miquel R. et al. Is it
possible to control hyperphosphataemia with diet, without inducing
protein malnutrition? Nephrol Dial Transplant. 1998;13 Suppl 3:65–7.
19. Kuhlmann MK. Management of hyperphosphatemia. Hemodialysis Int.
2006;10:338–45.
Leung et al. BMC Nephrology  (2015) 16:205 Page 5 of 6
20. Chiu YW, Teitelbaum I, Misra M, de Leon EM, Adzize T, Mehrotra R. Pill
burden, adherence, hyperphosphatemia, and quality of life in maintenance
dialysis patients. Clin J Am Soc Nephrol. 2009;4(6):1089–96.
21. Ahlenstiel T, Pape L, Ehrich JH, Kuhlmann MK. Self-adjustment of phosphate
binder dose to meal phosphorus content improves management of
hyperphosphataemia in children with chronic kidney disease. Nephrol Dial
Transplant. 2010;25(10):3241–9.
22. Chertow GM, Burke SK, Raggi P. Treat to Goal Working Group. Sevelamer
attenuates the progression of coronary and aortic calcification in
hemodialysis patients. Kidney Int. 2002;62(1):245–52.
23. Durose CL, Holdsworth M, Watson V, Przygrodzka F. Knowledge of dietary
restrictions and the medical consequences of noncompliance by patients
on hemodialysis are not predictive of dietary compliance. J Am Diet Assoc.
2004;104(1):35–41.
24. Yokum D, Glass G, Cheung CF, Cunningham J, Fan S, Madden AM. Evaluation
of a phosphate management protocol to achieve optimum serum phosphate
levels in hemodialysis patients. J Ren Nutr. 2008;18(6):521–9.
25. Ford JC, Pope JF, Hunt AE, Gerald B. The effect of diet education on
the laboratory values and knowledge of hemodialysis patients with
hyperphosphatemia. J Ren Nutr. 2004;14(1):36–44.
26. Ashurst Ide B, Dobbie H. A randomized controlled trial of an educational
intervention to improve phosphate levels in hemodialysis patients. J Ren
Nutr. 2003;13(4):267–74.
27. Morey B, Walker R, Davenport A. More dietetic time, better outcome? A
randomized prospective study investigating the effect of more dietetic time
on phosphate control in end-stage kidney failure haemodialysis patients.
Nephron Clin Pract. 2008;109(3):c173–80.
28. El-Gayar O, Timsina P, Nawar N, Eid W. Mobile applications for diabetes
self-management: status and potential. J Diabetes Sci Technol.
2013;7(1):247–62.
29. Kirwan M, Vandelanotte C, Fenning A, Duncan MJ. Diabetes self-management
smartphone application for adults with type 1 diabetes: randomized controlled
trial. J Med Internet Res. 2013;15(11), e235.
30. Charpentier G, Benhamou PY, Dardari D, Clergeot A, Franc S,
Schaepelynck-Belicar P, et al. The Diabeo software enabling
individualized insulin dose adjustments combined with telemedicine
support improves HbA1c in poorly controlled type 1 diabetic patients: a
6-month, randomized, open-label, parallel-group, multicenter trial
(TeleDiab 1 Study). Diabetes Care. 2011;34(3):533–9.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Leung et al. BMC Nephrology  (2015) 16:205 Page 6 of 6
